oNKo-Innate - Crunchbase Company Profile & Funding

Q: Where is oNKo-Innate's headquarters?

oNKo-Innate is located in Melbourne, Victoria, Australia.

Overview

oNKo-Innate

Heat Score

Company Performance Metrics

Score

Trend

About These Metrics

AI Content may contain mistakes and is not legal, financial or investment advice.

Learn more.

Growth Score - The measure of growth based on company activity, operational metrics, and investments

Growth Trend - The change in the growth score over the given time period

Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity

Heat Trend - The change in the heat score over the given time period

Recent Milestones

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

Raised Funding Round

Jan 1, 1970

Lorem ipsum dolor sit amet, consectetur

See more interactive data and historical milestones on desktop for the best experience

About oNKo-Innate

CB Rank

604181

oNKo-Innate is a discovery-stage company developing therapies that stimulate an innate immune response against cancer.

Founded

obfuscation

Private

Melbourne, Victoria, Australia

11-50

www.onko-innate.com/

Biotechnology

Pharmaceutical

Key People

Jai Rautela: Co-founder and CEO
Nicholas Huntington: Co-Founder and CSO
Past Role: Walter and Eliza Hall Institute of Medical Research, Head of Immunotherapy Laboratory

Details

Operating Status

Active

Company Type

For Profit

Founders

Jai Rautela, Nicholas Huntington

About the Company

oNKo-innate is a discovery-stage biotechnology company dedicated to target identification and pre-clinical immuno-oncology drug development. With our deep understanding of Natural Killer (NK) cells, we aim to be the first to truly therapeutically harness the cancer-fighting abilities of these remarkable white blood cells.

Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

oNKo-001

A reduced-potency IL-12 Fc fusion protein designed to reduce toxicity and improve pharmacokinetics while maintaining anti-tumor activity.

oNKo-037

A small molecule program targeting a novel immunotherapy checkpoint to enhance natural killer and T cell function by increasing sensitivity to IL-15 cytokines.